| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Innoviva, Inc. (INVA) has 3 insiders with recent SEC Form 4 filings, including 3 buys and 7 sells. INVA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 162.3K | $3.66M | - | |
| CFO | 51.3K | $1.16M | - | |
| Other | 48.3K | $1.09M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 21, 2017 | Desparbes Eric | SVP And CFO | Sell | 1,825 | $12.07 | $22,027.75 | -0.5% | |
| Nov 22, 2016 | Witek Theodore L Jr | Sr. VP &Chief Scientific Off. | Sell | 3,700 | $10.84 | $40,122.80 | -2.4% | |
| Nov 21, 2016 | Desparbes Eric | SVP And CFO | Sell | 1,800 | $10.89 | $19,602.00 | -0.8% | |
| Aug 22, 2016 | Desparbes Eric | SVP And CFO | Sell | 3,700 | $11.77 | $43,549.00 | -1.5% | |
| May 18, 2016 | Tyree James L51 | Director | Sell | 813 | $10.47 | $8,512.11 | -1.6% | |
| Aug 7, 2015 | Glaxosmithkline Plc | 10% Owner | Buy | 245,828 | $0.00 | - | +0.8% | |
| Jun 2, 2015 | Tyree James L51 | Director | Sell | 2,438 | $16.85 | $41,080.30 | -6.8% | |
| May 27, 2015 | Waltrip William H | Director | Sale+OE | 16,313 | $16.32 | $266,228.16 | -11.7% | |
| May 11, 2015 | Glaxosmithkline Plc | 10% Owner | Buy | 85,579 | $0.00 | - | +0.3% | |
| Mar 2, 2015 | Glaxosmithkline Plc | 10% Owner | Buy | 92,674 | $0.00 | - | +0.3% |